Physician profile
Payam Abrishami
NPI 1447288147
$4,871.03
in general payments reported to CMS, 2019-2025
31 companies · $705 in 2025
The $705 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $297 · 2021: $351 · 2022: $1,131 · 2023: $1,195 · 2024: $812 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.23 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $785.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $746.03 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $561.99 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Incyte Corporation | $367.32 | 2021-2025 | Opzelura |
| Pfizer INC. | $315.60 | 2019-2024 | |
| Leo Pharma INC. | $311.05 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $202.27 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $174.48 | 2020-2023 | Remicade, Stelara, Simponi Aria |
| Abbvie INC. | $164.89 | 2022-2024 | Botox |
| Novartis Pharmaceuticals Corporation | $147.21 | 2019-2025 | |
| Lilly USA, LLC | $139.68 | 2019-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $129.22 | 2019-2024 | |
| Ucb, INC. | $124.78 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.32 | 2022-2025 | Spevigo |
| Merz North America, INC. | $72.15 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71.33 | 2022-2024 | Sotyktu |
| Journey Medical Corporation | $68.96 | 2023-2025 | |
| Dermavant Sciences, INC. | $51.72 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $50.62 | 2019-2022 | |
| Almirall LLC | $44.13 | 2022 | |
| Arcutis Biotherapeutics, INC. | $35.72 | 2023-2024 | Zoryve |
| Epi Health, LLC | $35.21 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.09 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Strata Skin Sciences, INC. | $29.31 | 2022 | |
| Stemline Therapeutics INC. | $23.48 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.24 | 2020 | |
| Dermira, INC. | $22.62 | 2020 | |
| Verrica Pharmaceuticals INC. | $16.79 | 2025 | Ycanth |
| Prugen, INC. Pharmaceuticals | $15.19 | 2019 | |
| Aclaris Therapeutics, INC. | $14.56 | 2019 | |
| Vyne Pharmaceuticals INC. | $13.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Abrishami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.